Pipeline

We are developing novel siRNA therapies for the treatment of cardiovascular diseases, addressing a potential market value of over 10 billion US dollars.

  • Asset
  • Target
  • Discovery
  • Preclinical
  • IND Filing
  • Phase Ⅰ
  • Phase Ⅱ
  • Phase Ⅲ
  • SRSD107

  • Target A

  • SRSD101

  • Target B

  • SRSD216

  • Target C

  • SRSD131

  • Target D

  • SRSD158

  • Target E

  • SRSD229

  • Target F

  • SRSD230

  • Target G

  • SRSD258

  • Target H

Sirius Therapeutics, Inc., all rights reserved

Privacy Policy|Contact Us

为了更好的呈现效果,移动端请竖屏浏览